Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Transformed Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Leukapheresis; Biological: Lisocabtagene Maraleucel; Procedure: Lymph Node Biopsy; Procedure: Positron Emission Tomography; Drug: Zanubrutinib Sponsor: Adam Kittai Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Research